Forty pulses a second became a question about how the brain moves fluid. That is the genuinely surprising development behind 40 Hz Alzheimer’s research. Scientists first asked whether sensory stimulation could organize neural activity. In mouse models, they then found changes in amyloid pathology, immune-cell behaviour, and fluid transport. The most revealing experiments went further: they separated a measurable gamma response from the processes needed for amyloid removal. A brain rhythm was not the whole explanation.[1] [2] [3]
Quick answer: precisely timed light and sound have produced important discoveries in Alzheimer-like mouse models and feasible gamma responses in people. Small human studies have reported exploratory imaging findings, but reliable improvement in cognition and everyday function remains unestablished. The 673-participant HOPE study is completed, with no results posted in its official registry as checked on November 5, 2026. A PEMF Healing App listening routine is a separate consumer-wellness experience, not the device or exposure tested in those trials.[4] [5] [8] [10]
This guide follows the science from mice to human trials, explains what “40 Hz” actually specifies, and then gives you exact app programmes and a simple three-day listening orientation. The practical goal is a comfortable, manageable routine with honest observations, while keeping medical assessment and existing care in their proper place.
Why gamma rhythms became an Alzheimer’s research question
Neurons do not operate only as isolated cells. Their electrical activity can be coordinated in rhythms that researchers measure with electrophysiological recordings. Gamma describes a range of relatively fast neural activity involved in sensory processing and other network functions. It is a category of activity, not one universal brain state or a single medical frequency.[1] [9]
The MIT research approach is called GENUS, Gamma ENtrainment Using Sensory stimuli. In this approach, repeated sensory events are used to elicit rhythmic neural responses. Forty hertz means forty cycles or events per second, corresponding to a period of 25 milliseconds. What matters next is which physical event repeats: a light flash, an acoustic pulse, a beat percept, or something else. The brain does not become a uniform 40 Hz oscillator because a stimulus repeats at that rate.[2] [4]
Alzheimer’s disease involves interacting changes in amyloid, tau, neurons, synapses, and other aspects of brain function. That makes a timing-based intervention scientifically interesting, but it also makes translation demanding. A laboratory change in one pathological measurement has to be distinguished from preserving a person’s ability to remember, communicate, and manage daily life.[4] [5]
Three discoveries that made the field worth watching
2016: sensory timing changed amyloid measures in mice
Iaccarino and colleagues reported in Nature that gamma-driving experiments and noninvasive visual flicker altered amyloid measures and microglial behaviour in Alzheimer-like mice. Microglia are brain immune cells; the researchers examined changes in their appearance and association with amyloid. That opened a question about whether a sensory intervention could influence processes usually discussed in terms of cellular pathology.[1]
The finding was specific to the animals, stimulation conditions, brain regions, and measurement times studied. Increased amyloid association inside microglial cell bodies is not by itself a direct measurement of how much material was ultimately degraded. This distinction keeps the discovery interesting without turning a microscopy result into a claim that human disease was reversed.[1]
2019: combining sound and light extended the investigation
Martorell and colleagues added rhythmic sound and combined auditory and visual stimulation. In one experiment, six six-month-old 5XFAD mice per group received combined stimulation or no stimulation for comparison. After seven days, the stimulated animals had approximately 34% fewer neocortical plaques by count and 37% less plaque volume. These are striking between-group measurements from that mouse experiment, not percentages of human Alzheimer’s improvement.[2]
The study also examined neural responses, regional pathology, and selected mouse memory tasks. Its comparisons with other stimulation patterns supported the importance of the tested timing and modality. The implication was more precise than “frequency is healing”: a defined sensory pattern could interact with a particular biological system under particular experimental conditions.[2]
2024: the experiment reached brain-fluid transport
Murdock and colleagues investigated cerebrospinal fluid entering brain tissue and interstitial fluid leaving it. In 5XFAD mice, combined gamma sensory stimulation increased tracer measures of these movements. The work implicated astrocytic aquaporin-4, a water-channel protein, alongside vascular dynamics and signalling involving vasoactive intestinal peptide, or VIP, interneurons.[3]
The most revealing result was a separation of mechanisms. When the researchers inhibited VIP interneurons, stimulation-related arterial pulsatility and amyloid clearance were attenuated even though the measured gamma response was not substantially suppressed. In other words, observing a 40 Hz neural response did not guarantee that the downstream clearance process remained intact.[3]
A fast neural rhythm was associated with much slower vascular processes. The arteries were not simply pulsing forty times a second. This is an important new lens: the relevant biology may depend on how neural activity recruits fluid and vascular dynamics, rather than on a frequency number acting alone. It remains a mouse mechanism, not a demonstration that an app or consumer device clears human plaques.[3]
What the human trials have actually shown
The central human question is not whether a brain can respond rhythmically. It is whether a defined intervention helps people maintain cognition and everyday function with acceptable safety. Early studies are useful because they establish feasibility and identify measurements to investigate in larger trials.[4] [5]
| Study | What was investigated | What the finding means |
|---|---|---|
| Chan and colleagues, 2022 | A small randomized pilot assigned 15 participants, eight active and seven control, to daily audiovisual stimulation or comparison. | Feasibility and exploratory signals were reported. Standard global cognitive measures did not show significant between-group differences; some exploratory analyses had still smaller samples.[4] |
| OVERTURE, 2024 publication | 76 participants were randomized in a six-month active-versus-sham sensory-stimulation study. | The reported 69% lower whole-brain volume loss relative to sham was an exploratory MRI finding. The study was not powered to establish efficacy, and important cognitive scales did not separate significantly.[5] |
| Open-label extension, 2025 | Five self-selected participants continued in a long-term extension with no concurrent randomized control group. | Interesting individual trends cannot establish causality. Very small samples, prior treatment differences, and external comparisons limit interpretation.[6] |
| HOPE, current registry | 673 total participants in an active-versus-sham pivotal device study with cognitive and functional outcomes. | The registry lists completion but does not post outcome results as checked November 5, 2026. Total enrollment is not the number receiving active stimulation.[10] |
The “69%” headline has a specific denominator
OVERTURE reported 69% less MRI-measured whole-brain volume loss relative to sham in an exploratory comparison over six months. It did not report 69% plaque clearance, 69% brain regeneration, or 69% overall reduction in Alzheimer’s disease. The publication reported no significant separation on MADCOMS, ADAS-Cog14, and CDR-SB. Amyloid PET comparisons also did not establish a treatment effect.[5]
Imaging findings can be valuable research leads. They become much more persuasive when they agree with prespecified, clinically meaningful outcomes in sufficiently powered studies. A relative percentage should always travel with the measurement, comparator, duration, and uncertainty that produced it.
What the evidence syntheses add
A 2025 meta-analysis did not find statistically significant pooled improvement in cognition or its daily-living outcome category. The cognition estimate had a confidence interval crossing no effect. Its positive imaging analysis was highly heterogeneous and included overlapping reports from OVERTURE, rather than a set of entirely independent replications. The published participant totals also differ across sections, so repeating one unqualified aggregate would give a false impression of precision.[8]
A broader review published online in December 2025, with a 2026 journal citation, covered 62 heterogeneous auditory-gamma studies across healthy and clinical populations. Those were not 62 Alzheimer’s treatment trials. The review found that neurophysiological responses did not reliably predict cognitive or biological benefit. This reinforces the lesson from the mouse mechanism work: a measured response is a starting point for a clinical question, not its answer.[9]
A fresh disclosure readers should know about
A correction published on November 4, 2026 added disclosures to the five-person extension report, including MIT licensing revenue associated with GENUS, related patents, and a researcher’s Cognito consultancy. These disclosures did not announce new efficacy results. They help readers evaluate interests alongside methods, sample sizes, and replication. Financial involvement is a reason for transparency, not an automatic reason to dismiss the research.[7]
HOPE: what is current, and what is still awaited
The official record for NCT05637801, the HOPE study, lists 673 actual participants, primary completion on June 22, 2026, and overall completion on August 17, 2026. Its last posted update was September 9, 2026. The primary outcome compares change in an integrated cognitive and daily-function scale, iADMARS, between active and sham groups over twelve months.[10]
As checked on November 5, 2026, the registry has no posted results. No decisive public pivotal efficacy result was verified in this review. That means the completed study should be described as a study awaiting a verified readout, not as a success or a failure. Any later release should be assessed using the actual outcome estimates, uncertainty, analyzed participants, missing data, and safety findings.
The study used an investigational audiovisual system, Spectris AD, with approximately sixty minutes of daily use under its trial procedures. That exposure is not an instruction to run an app, coil, or home strobe for an hour. A clinical device trial includes screening and a defined sensory exposure that a catalogue label cannot reproduce.[10]
FDA terms do not describe a therapeutic frequency
No FDA marketing authorization for Spectris AD as an Alzheimer’s treatment was identified in the reviewed sources as of November 5, 2026. The official trial record describes an unapproved device. Permission to conduct an investigational device study and a Breakthrough Device designation are different from authorization to market a device for treatment. None creates an “FDA-approved 40 Hz frequency.”[10] [11] [12]
Same number, different exposure: the distinction every reader needs
“40 Hz” supplies a rate. It does not specify the complete intervention. A sound carrier, pulse repetition, dichotic beat, light modulation, magnetic field, and body vibration are physically different quantities. The delivery route determines which receptors and tissues receive the stimulus.[2] [4] [13]
| Presentation | What physically reaches the user | Responsible interpretation |
|---|---|---|
| Continuous 40 Hz tone | A low-frequency acoustic pressure oscillation. | It is not the same as a sequence of brief auditory events used in sensory-gamma experiments. |
| Rhythmic auditory pulses | Repeated clicks or bursts, with their own waveform and audible content. | The carrier content and repetition rate are separate parameters; the tested exposure still needs to be specified. |
| Binaural beat | Different acoustic tones delivered separately to the two ears. | An auditory percept is not automatically equivalent to audiovisual GENUS or a demonstrated Alzheimer’s outcome. |
| Synchronized light and sound | Timed visual and auditory input from a defined research system. | This is the relevant clinical sensory-stimulation pathway, not evidence for every product using the same number. |
| PEMF coil | A time-varying magnetic field dependent on the drive system, applicator, and exposure. | Its field strength, waveform, geometry, and placement require their own characterization and evidence. |
| Haptic wearable | Mechanical vibration coupled into the body. | A separate sensory experience, not the clinical device tested in HOPE. |
Stereo headphones can preserve left-right channel separation when a programme uses dichotic audio. Summing channels to mono changes the presentation. Bone-conduction headphones should not be assumed to isolate the ears in the same way because vibration can reach the opposite side of the skull. None of these routing choices establishes brain entrainment or disease modification in an individual listener.[13] [14]
Precision, evolving sound, and the limits of the static-tone story
A recorded programme can evolve in texture, harmonic balance, or intensity while still following a predetermined sequence. That offers a different listening experience from one continuous tone. But the exact contents of this premium programme are not publicly documented in the material reviewed, so this guide does not invent its seven phase functions or internal signal design.
Precisely timed sensory stimulation matters because it defines an experiment. The strongest 40 Hz mouse findings themselves involved repeated, carefully specified stimulation. They therefore do not support a blanket claim that static or repetitive signals are biologically useless. Nor do the reviewed studies show that changing harmonics prevents cellular adaptation or that a phased recording is clinically superior. Rife-labelled disease-frequency lists are not evidence for Alzheimer’s efficacy; contemporary evidence depends on tested exposures and outcomes, not a label or historical tradition.[2] [9] [13]
PEMF Healing App programmes: a clear starting point
The primary catalogue resource for this guide is Alzheimer’s Neural Rhythm Restoration MIT 40 hz Gamma Anchored 7 Phase Energetics. Its exact title identifies seven phases. The public page is premium and does not provide a verified runtime, phase map, or compatible-hardware specification.
The words “MIT” and “Restoration” appear in the catalogue name. They do not establish that MIT created, licensed, endorsed, or clinically tested this app programme, and they do not establish restoration of a user’s brain. The resource is presented here as an app listening option, clearly separate from the research intervention.
The following nine exact programme titles provide additional navigation. Titles containing memory, brain, sleep, or other outcome language are platform labels, not promises or verified medical indications. No substance layers or internal substance frequencies are inferred from them.
- 40Hz Gamma Increase Focus, Cognitive, Memory Recall, Perception advanced energetics
- Memory Repair and Improve Advanced energetics
- Brain Fog Recovery, Focus, Memory, Clarity, Peak Cognition Energetics
- Amygdala Left – Right Binaural, Memory, Emotion, Cognition… Energetics
- 30Hz Gamma Perform Rich Task – Complex Information Processing
- Sleep Energetics
- Quality of Sleep, Deprivation, Insomnia Energetics
- Bb: Sleep Decent, Deep Rain Rest and Relaxation ASMR
- Sleep, Deep Night Forest Owl Parasympathetic Haptic Energetics
How to start: one listening route, a static screen, and a stop control
This is an optional adult listening orientation, not an Alzheimer’s treatment protocol. Anyone with diagnosed dementia, concerning memory changes, epilepsy, photosensitivity, or another neurological vulnerability should discuss new stimulation use with their clinician before attempting this routine. Where cognitive impairment affects consent or communication, a caregiver should help follow the person’s care plan, respect refusal, and never turn the routine into an imposed experiment.[15] [17] [21]
- Check the listing first. Open the primary programme in the PEMF Healing App. Read its current playback, safety, and supported-output instructions. If its guidance is absent or uncertain, ask the platform rather than infer compatibility.
- Start with audio alone. Sit comfortably while awake, use a supported headphone or speaker route, and make playback easy to stop. Stereo headphones are appropriate when channel separation is required by the listing; no headset is a medical guarantee.
- Keep the display static. Do not add a flashing lamp, strobing screen, DIY synchronizer, or improvised visual stimulus. This routine does not attempt audiovisual GENUS.
- Use a low, comfortable level. Begin with a brief comfort check. A louder track is not a stronger therapeutic dose, and a phone’s volume percentage is not a calibrated sound-pressure measurement. Stop for discomfort, tinnitus, headache, dizziness, anxiety, or unusual symptoms.[18]
- Keep ordinary care unchanged. Do not change medicines, clinical devices, appointments, or sleep management because of a programme name or a better-feeling session.
The short preview limits below are editorial pacing choices for comfort and routine fit, not evidence-derived exposure doses. Previewing ten minutes does not imply completing all seven phases. If a programme finishes sooner, stop at its natural end. Longer or complete playback should follow the current listing and appropriate professional guidance, not extrapolation from the clinical trial.
A three-day app routine: primary first, two optional companions
Each day begins with the same primary programme. The companions give a choice between a memory-themed listening option, another gamma-labelled recording, and a restful soundscape. You can stop after the primary, omit either companion, or skip the entire day. The maximum plan contains twenty minutes of playback and two ten-minute quiet gaps, a forty-minute block if run consecutively. There is no need to fill that block or to delay bedtime for it.
| Day | Exact linked order and timing | Practical action and observation |
|---|---|---|
| Day 1: establish comfort | First, Alzheimer’s Neural Rhythm Restoration MIT 40 hz Gamma Anchored 7 Phase Energetics: up to 10 minutes as a preview.Take a 10-minute quiet gap.
Optionally, Memory Repair and Improve Advanced energetics: up to 5 minutes as a preview. Take another 10-minute quiet gap. Optionally, Bb: Sleep Decent, Deep Rain Rest and Relaxation ASMR: up to 5 minutes as a preview. |
Use audio only while awake. Keep setup and volume simple. Write one line about comfort and whether the routine fitted the day. Do not use memory tests or symptom changes to diagnose a response. |
| Day 2: compare listening preference | First, Alzheimer’s Neural Rhythm Restoration MIT 40 hz Gamma Anchored 7 Phase Energetics: up to 10 minutes as a preview.Take a 10-minute quiet gap.
Optionally, 40Hz Gamma Increase Focus, Cognitive, Memory Recall, Perception advanced energetics: up to 5 minutes as a preview. Take another 10-minute quiet gap. Optionally, Bb: Sleep Decent, Deep Rain Rest and Relaxation ASMR: up to 5 minutes as a preview. |
Keep the primary preview, output level, and listening route unchanged. Compare preference only: did you prefer the companion or the quiet gap? Changing recordings does not constitute a controlled efficacy test. |
| Day 3: choose the simplest version | First, Alzheimer’s Neural Rhythm Restoration MIT 40 hz Gamma Anchored 7 Phase Energetics: up to 10 minutes as a preview.Take a 10-minute quiet gap.
Optionally, Memory Repair and Improve Advanced energetics: up to 5 minutes as a preview. Take another 10-minute quiet gap. Optionally, Bb: Sleep Decent, Deep Rain Rest and Relaxation ASMR: up to 5 minutes as a preview. |
Keep only what remains comfortable and useful to your routine. One recording or ordinary quiet may fit better than three. Note any unwanted effects and discuss relevant concerns with a clinician. |
After the three days, take a playback-free day and review whether the routine was pleasant and practical. This pause is for preference and organisation, not an established biological reset. There is no evidence-based instruction here to repeat a treatment cycle, increase output, or add devices. Feeling calmer or more attentive is a personal observation, not a measure of amyloid, tau, brain volume, or Alzheimer’s progression.
Optional hardware: decide on the output before adding it
Audio, PEMF, and haptics can be discussed as distinct consumer-wellness pathways. Combining them changes the experience and makes it harder to know which component affected comfort. It does not create a tested Alzheimer’s intervention. The audio-only routine above avoids assuming hardware compatibility from a premium programme title.
Affiliate disclosure: some links below are affiliate links. PEMF Magazine may receive a commission from qualifying purchases. These resources identify products, not clinically established Alzheimer’s benefits.
| Layer | Resource | How it fits responsibly |
|---|---|---|
| Programme access | Frequency Healing App | Use the current listing and supported playback instructions. The programme menu is not a medical prescription. |
| Consumer PEMF | iTorus i2 or iTorus i5 | Confirm this programme’s compatibility, supported connection, output, and placement with the platform and manufacturer before use. This article does not recommend a coil on the head or neck. Implanted electronic devices, pregnancy, or medical uncertainty require professional review.[20] |
| Haptic experience | Woojer Vest 4. Use code EPEMF10 at checkout. | Mechanical vibration from supported audio is a separate output, not clinical audiovisual GENUS. Follow manufacturer restrictions and remain awake with access to the stop control. Do not add it to the introductory routine without appropriate compatibility and safety review. |
| Optional ritual | Metatronic Flower of Life Dual Frequency Imprinter | A separate ritual resource, not a method of amyloid clearance or a substitute for care. Keep liquids away from electronics, follow handling instructions, and do not ingest a substance because a programme names it. |
Best practices that make a daily routine more useful
Give ordinary timing and activity the first place
NIA guidance for Alzheimer’s-related sleep problems includes regular routines, daylight, appropriate daytime activity, and attention to the sleep environment. These ordinary supports have their own practical role. They should not be rebranded as an app’s plaque-clearing effect. Plan listening around the person’s day rather than rearranging the day to chase an exposure number.[19]
Use enjoyable, familiar activities when appropriate, including conversation or preferred music. For a person living with dementia, the activity should fit their abilities and preferences. Consent, comfort, and the caregiver’s observations matter more than completing a playlist. If the person refuses, becomes distressed, or cannot communicate comfort reliably, stop and follow the clinical care plan.[21]
Keep an imprinter practice separate from the health claim
If an imprinter is part of your personal routine, use it as a clearly separate ritual. Keep equipment dry, handle cables safely, and maintain ordinary hydration. There is no established evidence in the research reviewed here that imprinted water reproduces sensory gamma stimulation, clears amyloid, or improves Alzheimer’s outcomes. It does not replace medicines, nutrition, or a clinician’s advice.
Track routine fit, not an imagined biomarker
A useful one-line log can say: “Audio comfortable; stopped at eight minutes; preferred quiet afterward.” That is enough. A home comfort log cannot reveal microglial activity, glymphatic transport, brain shrinkage, or clinical cognitive change. Avoid repeatedly testing a family member’s memory to judge whether a recording “worked.” Clinical assessment answers a different question.
Safety and when to seek clinical help
Memory change deserves assessment. Repeated questions, getting lost, trouble following instructions, or difficulty managing familiar tasks should prompt a conversation with a qualified clinician. Not every memory problem is Alzheimer’s, and some causes require different care. Do not use an app response to decide whether assessment is necessary.[15]
Sudden confusion is a different situation. An abrupt change in awareness or orientation requires immediate medical assessment. Seek emergency help using the local emergency number rather than attempting a listening session.[16]
Do not improvise flicker. Photosensitive seizures can be triggered by flashing patterns, and sensitivity can extend into frequencies that include 40 Hz. Neither “gamma” nor “nonpharmacologic” means seizure-safe. Seizure history, photosensitivity, light-triggered migraine, and other neurological concerns require professional advice; this guide provides no instructions for recreating research light exposure.[17]
Protect hearing and respect discomfort. Use low, comfortable audio and stop for new or worsening tinnitus, headache, distress, dizziness, or other unwanted effects. Do not compensate for hearing difficulty by continually increasing output; seek appropriate hearing advice. Comfortable listening is not a test of treatment strength.[18]
Review physical devices separately. Magnetic devices can be unsuitable around implanted electronic equipment, and device-specific restrictions matter. A generic spacing rule for everyday electronics is not a universal safe distance for a PEMF coil. Follow the actual device and implant instructions with professional guidance where needed.[20]
The meaningful takeaway: 40 Hz research is worth following because controlled sensory timing opened questions about neural networks, immune cells, vascular dynamics, and brain-fluid transport. For readers, the immediate practical value is clearer scientific understanding and a carefully bounded listening routine. The next major human result must be evaluated on what people can do in daily life, not just on whether their brain responds to a rhythm.
Educational and wellness disclaimer: This article is for educational purposes only. It does not provide medical advice, diagnosis, or treatment, and it does not establish that a programme, recording, or device produces a particular result. Do not delay or replace licensed clinical care or discontinue prescribed treatments. Consult a qualified healthcare professional for memory symptoms, neurological conditions, seizures, photosensitivity, hearing concerns, pregnancy, implanted electronic devices, or questions about whether stimulation is appropriate. Follow current platform and manufacturer instructions.
Related Articles
- Human Biological Clock: Circadian and Ultradian Rhythm Guide
- The Light Eye: Polarity, Perception and Frequency Explained
- Bioelectric Wellness Devices Explained
References
- Iaccarino HF et al. (2016). Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. Mouse research; read with the journal’s linked corrections. Direct source.
- Martorell AJ et al. (2019). Multi-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition. Cell. Mouse study. Direct source.
- Murdock MH et al. (2024). Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature. Mouse mechanistic study. Direct source.
- Chan D et al. (2022). Gamma frequency sensory stimulation in mild probable Alzheimer’s dementia patients: Results of feasibility and pilot studies. PLOS ONE. Direct source.
- Hajós M et al. (2024). Safety, tolerability, and efficacy estimate of evoked gamma oscillation in mild to moderate Alzheimer’s disease. Frontiers in Neurology. OVERTURE study. Direct source.
- Chan D et al. (2025). Gamma sensory stimulation in mild Alzheimer’s dementia: An open-label extension study. Alzheimer’s & Dementia. Direct source.
- Correction to the open-label extension report. (November 4, 2026). Alzheimer’s & Dementia. Added financial and patent disclosures. Direct source.
- Ang S et al. (2025). The safety and efficacy of gamma frequency auditory and visual stimulation in the treatment of Alzheimer’s disease: a systematic review and meta-analysis. Translational Psychiatry. Direct source.
- Bolland E et al. (Online December 2025; journal citation 2026). Efficacy of auditory gamma stimulation for cognitive decline: a systematic review of individual and group differences across cognitively impaired and healthy populations. npj Aging. Direct source.
- ClinicalTrials.gov. NCT05637801: A Pivotal Study of Sensory Stimulation in Alzheimer’s Disease, HOPE Study. Current status and results checked November 5, 2026. Direct trial record; Official structured record.
- U.S. Food and Drug Administration. IDE Approval Process. Study permission and restrictions on commercialization. Direct source.
- U.S. Food and Drug Administration. Breakthrough Devices Program. Designation and marketing authorization are distinct. Direct source.
- Ingendoh RM et al. (2023). Binaural beats to entrain the brain? A systematic review of the effects of binaural beat stimulation on brain oscillatory activity, and the implications for psychological research and intervention. PLOS ONE. Direct source.
- Stenfelt S. (2012). Transcranial attenuation of bone-conducted sound when stimulation is at the mastoid and at the bone conduction hearing aid position. Otology & Neurotology. Direct source.
- National Institute on Aging. Memory Problems, Forgetfulness, and Aging. Direct source.
- NHS. Sudden confusion (delirium). Direct source.
- Epilepsy Society. Photosensitive epilepsy. Direct source.
- National Institute on Deafness and Other Communication Disorders. Noise-Induced Hearing Loss and Tinnitus. Hearing-risk guidance; Tinnitus guidance.
- National Institute on Aging. Managing Sleep Problems in Alzheimer’s Disease. Direct source.
- National Center for Complementary and Integrative Health. Magnets for Pain: What You Need To Know. Magnetic-device safety and medical-care cautions. Direct source.
- National Institute on Aging. Adapting Activities for People With Alzheimer’s Disease. Direct source.